GFAP, or glial fibrillary acidic protein, supports star-shaped brain cells called astrocytes that help maintain nerve cell ...

Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather ...

In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

Promising therapy for relapsing multiple sclerosis Date: February 18, 2010 Source: University of Utah Health Sciences Summary: Scientists have found that adding a humanized monoclonal antibody ...

Panelists discuss how BTK inhibitors represent a promising new oral therapy class that could address both inflammatory and ...

Risky stem cell transplant for MS could help with symptoms 04:44. An experimental treatment for multiple sclerosis is showing promise in stopping symptoms of the disease, according to a new study ...

Among patients with relapsing–remitting multiple sclerosis, daclizumab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse rate and lesions, as ...

A person's total number of visits to multiple sclerosis clinics is not associated with a lower risk of death, a study on ...

An experimental stem cell therapy proved effective and safe in patients with a relapsing form of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, new ...

Imaging studies at the NIH Clinical Center showed that chronic active lesions with a paramagnetic rim exerted ongoing tissue ...

Most disability accumulation in relapsing MS is not associated with overt relapses, challenging the current clinical distinction of relapsing and progressive forms of the disease, researchers report.

Differentiating Between Progressive & Relapsing MS Given that disability progression is essential for a diagnosis of PPMS, physicians seek telltale signs that help them differentiate among the ...